Not A Total Fail For Orexigen
This article was originally published in Scrip
You may also be interested in...
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
After two years of almost nonexistent sales, analysts are ringing the death knell for the obesity market as revenues of once-promising obesity drugs continue to decline. The expectation is that virtually all of the major marketing partners will exit their respective partnerships in the near-term and more than one player could run out of cash.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.